Christian Cabanlong


Professional Certifications and Education

Ph.D., University of Arkansas for Medical Sciences, 2016-Present

B.S. Biology, minors, Chemistry and Asian studies, University of New Mexico, 2014

Research Experience

Currently, I am starting my fourth year as a Ph.D. at the University of Arkansas for Medical Sciences. Presently my work focuses on a large group of psychoactive compounds known as synthetic cannabinoids. These compounds are sold as legal alternatives to cannabis, but a majority of them produce severe and sometimes fatal adverse effects. My dissertation project revolves around quantifying and understanding the mechanism behind these adverse effects. That information has potential influence in scheduling these drugs and treatment of adverse effects. My goal is to make a profile for each of these relatively unknown compounds that include; their ability to induce Toxicity, inflammation and ease of reversibility via antagonist.

Past experiences include summer research at the University of New Mexico Health Science Senter funded by the McNair program. As well as a 2 year research assistantship under the University of New Mexico Post-bachelorette program.

The summer research with the McNair involved looking at how the lumican gene can exacerbate the EAE disease state in mice due to the effects on differentiated TH-17 cells. In the 2 years of research exposure I looked at how the treatment of Schistosoma mansoni infected mice with praziquantel only affected the mature worms and not the juvenile worms through differential expression of drug efflux genes.

Research interests

Currently my research interest is drug pharmacodynamics, meaning the drug effects on the body. Whether it is drugs of abuse or novel therapeutic compounds both interact canonically with a receptor and have immediate and long-term effects. That interaction, subsequent effects and participating mechanisms are what I take interest in when designing research questions.

Recent Publications

Griffin BA, Caperton CO, Russell LN, Cabanlong CV, Wilson CD, Urquhart KR, et al. (2019). “In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome.” J Pharmacol Exp Ther 370: 9-17.

Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, et al. (2019). “Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Delta(9)-Tetrahydrocannabinol and JWH-018.” J Pharmacol Exp Ther 369: 259-269.